All anti-CD20 monoclonal antibodies have similar efficacy and risks: Commentary

Mult Scler. 2022 Oct;28(12):1847-1848. doi: 10.1177/13524585221122219.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Antibodies, Monoclonal* / therapeutic use
  • Antineoplastic Agents*
  • Humans

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents